IHH Healthcare ties up with Singapore's Lucence for blood-based biopsy services

IHH also took part in the genomic medicine firm’s $20m Series A funding.

Singapore-based genomic medicine company Lucence will be providing IHH Healthcare’s patients access to cancer diagnostics and AI-driven analytics as IHH Healthcare has led a minority investment in it as part of a $20m Series A funding, according to a press release.

“IHH looks to drive greater synergies with Lucence and co-develop solutions for patients, as well as explore opportunities to sharpen our precision medicine capabilities with other like-minded partners across our 10-country network,” IHH Healthcare CEO (designate) Kelvin Loh said.

Lucence uses blood-based liquid biopsy in analysing tumours, which is considered to be less invasive than tissue biopsies. It focuses on Asia-prevalent cancers like lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers.

IHH recently worked with a Singaporean start-up in improving the estimated bill size for patients ahead of admission through predictive AI.